{"filing":{"accession_number":"0001104659-26-104455","cik":"0001962738","ticker":"CASIF","company_name":"CASI Pharmaceuticals, Inc.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"tm2624664d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1962738/000110465926104455/tm2624664d1_6k.htm"},"events":[{"id":31140,"run_id":28565,"accession_number":"0001104659-26-104455","anchor_item_number":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics to BioMarin Pharmaceutical, receiving approximately $5.9 million in net cash proceeds at closing plus potential contingent milestone payments. This is a material disposition of an equity investment that affects the company's financial position and asset base. While it could be characterized as a divestiture or asset sale (financial_other), it does not fit the specific M\u0026A categories (ma_activity applies to acquisitions/mergers of the registrant itself, not sales of subsidiary interests), making financial_other the most appropriate classification.","company_name":"CASI Pharmaceuticals, Inc.","ticker":"CASIF","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33944,"accession_number":"0001104659-26-104455","item_number":null,"item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics to BioMarin Pharmaceutical, receiving approximately $5.9 million in net cash proceeds at closing plus potential contingent milestone payments. This is a material disposition of an equity investment that affects the company's financial position and asset base. While it could be characterized as a divestiture or asset sale (financial_other), it does not fit the specific M\u0026A categories (ma_activity applies to acquisitions/mergers of the registrant itself, not sales of subsidiary interests), making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:01:46.521351+00:00","company_name":"CASI Pharmaceuticals, Inc.","ticker":"CASIF","filing_date":"2026-09-02"}]}